Who are APD403 IV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Sevoflurane Inhalation Liquid, Intranasal ketamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apd403-iv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

APD403 IV — Competitive Intelligence Brief

APD403 IV (APD403 IV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Anesthesiology.

phase 2 NMDA receptor antagonist NMDA receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

APD403 IV (APD403 IV) — Acacia Pharma Ltd. APD403 IV is an anesthetic agent that works by blocking N-methyl-D-aspartate (NMDA) receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
APD403 IV TARGET	APD403 IV	Acacia Pharma Ltd	phase 2	NMDA receptor antagonist	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Sevoflurane Inhalation Liquid	Sevoflurane Inhalation Liquid	Damanhour Teaching Hospital	marketed	Volatile general anesthetic	GABA-A receptor, NMDA receptor
Intranasal ketamine	Intranasal ketamine	Rhode Island Hospital	marketed	NMDA receptor antagonist	NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

Turku University Hospital · 3 drugs in this class
H. Lundbeck A/S · 2 drugs in this class
Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
Shalvata Mental Health Center · 2 drugs in this class
New York State Psychiatric Institute · 2 drugs in this class
Auris Medical AG · 1 drug in this class
AstraZeneca · 1 drug in this class
Alameda Health System · 1 drug in this class
Centre Hospitalier Universitaire de Nice · 1 drug in this class
Asker & Baerum Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). APD403 IV — Competitive Intelligence Brief. https://druglandscape.com/ci/apd403-iv. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab